Data from Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma

Abstract

<div>Abstract<p><b>Purpose:</b> Sensitize melanomas to apoptosis and inhibit their growth and metastatic potential by compounds that mimic the activities of activating transcription factor 2 (ATF2)-driven peptides.</p><p><b>Experimental Design:</b> Small-molecule chemical library consisting of 3,280 compounds was screened to identify compounds that elicit properties identified for ATF2 peptide, including (<i>a</i>) sensitization of melanoma cells to apoptosis, (<i>b</i>) inhibition of ATF2 transcriptional activity, (<i>c</i>) activation of c-Jun NH<sub>2</sub>-terminal kinase (JNK) and c-Jun transcriptional activity, and (<i>d</i>) inhibition of melanoma growth and metastasis in mouse models.</p><p><b>Results:</b> Two compounds, celastrol (CSL) and acetyl isogambogic acid, could, within a low micromolar range, efficiently elicit cell death in melanoma cells. Both compounds efficiently inhibit ATF2 transcriptional activities, activate JNK, and increase c-Jun transcriptional activities. Similar to the ATF2 peptide, both compounds require JNK activity for their ability to inhibit melanoma cell viability. Derivatives of CSL were identified as potent inducers of cell death in mouse and human melanomas. CSL and a derivative (CA19) could also efficiently inhibit growth of human and mouse melanoma tumors and reduce the number of lung metastases in syngeneic and xenograft mouse models.</p><p><b>Conclusions:</b> These studies show for the first time the effect of CSL and acetyl isogambogic acid on melanoma. These compounds elicit activities that resemble the well-characterized ATF2 peptide and may therefore offer new approaches for the treatment of this tumor type.</p></div>